Abstract
Purpose
Systemic exposure to niflumic acid was significantly increased when talniflumate was given orally together with a meal. To clarify the underlying mechanism, an in vitro dissolution study of talniflumateonducted at different pH values, and magnesium hydroxide was co-administered in healthy volunteers.
Methods
In vitro dissolution tests of talniflumate tablets were performed in a USP Paddle apparatus at pH 1.2, 4.0, and 6.8, respectively, in the presence and absence of Tween 80 (2%). Serial samples of the talniflumate solution were taken and analyzed on a high-performance liquid chromatography (HPLC)/ultraviolet system. Healthy volunteers were divided randomly into two groups, and each volunteer received a single 740-mg dose of talniflumate, with or without 1 g of magnesium hydroxide, following an overnight fast. The plasma concentrations of niflumic acid were measured using HPLC coupled with tandem mass spectrometry.
Results
Talniflumate was completely insoluble at each of the tested pHs in the absence of Tween 80. The drug was slowly and steadily dissolved (54%) at pH 4 in the presence of the surfactant, but the extent of dissolution was only 15 and 0.5% at pH 1.2 and 6.0, respectively. Magnesium hydroxide co-administered with talniflumate significantly increased systemic exposure to niflumic acid: the mean maximum plasma concentration (C max) and area under the concentration–time curve (AUC inf) were augmented by 2.0- and 1.9-fold, respectively, compared with those in the absence of the antacid. Magnesium hydroxide significantly accelerated the appearance of niflumic acid in plasma by 2.8-fold.
Conclusions
Magnesium hydroxide increases the rate and extent of systemic exposure to niflumic acid owing to the enhanced solubility of talniflumate and absorption of niflumic acid. The possible combination of talniflumate and an antacid should be considered in the development of pharmaceutical formulations.
This is a preview of subscription content, log in via an institution to check access.
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.References
Kang W, Kim K, Kim EY, Kwon KI, Bang JS, Yoon YR (2008) Effect of food on systemic exposure to niflumic acid following postprandial administration of talniflumate. Eur J Clin Pharmacol 64:1027–1030
Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) (1997) Guidance for industry. Modified release solid oral dosage forms: scale up and post approval changes (SUPAC): chemistry, manufacturing and controls, in vitro dissolution testing and in vivo bioequivalence documentation. FDA, Rockville
Jang DJ, Park JS, Ko HR, Jee JP, Kim JK, Kim ST, Kim CK (2005) Simultaneous determination of niflumic acid and its prodrug, talniflumate in human plasma by high performance liquid chromatography. Biomed Chromatogr 19:32–35
Kang W, Kim K (2009) Determination of talniflumate and niflumic acid in human plasma by liquid chromatography–tandem mass spectrometry. Anal Sci 25:571–574
Wilson P, Clark GW, Anselmino M, Welch NT, Singh S, Perdikis G, Hinder RA (1993) Comparison of an intravenous bolus of famotidine and Mylanta II for the control of gastric pH in critically ill patients. Am J Surg 166:621–624
Neuvonen PJ, Kivisto KT (1988) Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids. Eur J Clin Pharmacol 35:495–501
Schmidt C, Baumeister B, Kipnowski J, Miederer SE, Vetter H (1998) Magaldrate stimulates endogenous prostaglandin E2 synthesis in human gastric mucosa in vitro and in vivo. Hepatogastroenterology 45:2443–2446
Konturek SJ, Brzozowski T, Drozdowicz D, Nauert C (1990) Role of intragastric pH in cytoprotection by antacids in rats. Eur J Pharmacol 176:187–195
Kamiya S, Yamaguchi H, Osaki T, Taguchi H, Fukuda M, Kawakami H, Hirano H (1999) Effect of an aluminum hydroxide-magnesium hydroxide combination drug on adhesion, IL-8 inducibility, and expression of HSP60 by Helicobacter pylori. Scand J Gastroenterol 34:663–670
Nagai N, Fukuhata T, Ito Y, Usui S, Hirano K (2009) Preventive effect of co-administration of water containing magnesium ion on indomethacin induced lesions of gastric mucosa in adjuvant-induced arthritis rat. Biol Pharm Bull 32:116–120
Mäenpää J, Tarpila A, Jouhikainen T, Ikävalko H, Löyttyniemi E, Perttunen K, Neuvonen PJ, Tarpila S (2004) Magnesium hydroxide in ibuprofen tablet reduces the gastric mucosal tolerability of ibuprofen. J Clin Gastroenterol 38:41–45
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, E., Kang, W. Contribution of pH to systemic exposure of niflumic acid following oral administration of talniflumate. Eur J Clin Pharmacol 67, 425–428 (2011). https://doi.org/10.1007/s00228-010-0980-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-010-0980-5